A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch

Objectives: The primary objective of this multicentre, prospective, observational study was to assess whether there is improvement in the patients’ quality of life under treatment with rivastigmine transdermal patch, as it is evaluated both by patients and their caregivers. Compliance to treatment a...

Full description

Bibliographic Details
Main Authors: Vassileios Vagenas, Georgios S Vlachos, Nikoleta Vlachou, Dimitrios Liakopoulos, Michail E Kalaitzakis, Michail Vikelis
Format: Article
Language:English
Published: SAGE Publishing 2015-06-01
Series:SAGE Open Medicine
Online Access:https://doi.org/10.1177/2050312115587795
id doaj-8db347b4abcc41e9bc52f37031c5a63e
record_format Article
spelling doaj-8db347b4abcc41e9bc52f37031c5a63e2020-11-25T03:00:58ZengSAGE PublishingSAGE Open Medicine2050-31212015-06-01310.1177/205031211558779510.1177_2050312115587795A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patchVassileios Vagenas0Georgios S Vlachos1Nikoleta Vlachou2Dimitrios Liakopoulos3Michail E Kalaitzakis4Michail Vikelis5Department of Neurology, SismanogleioGeneralHospital, Athens, GreeceMedical Department, Novartis (Hellas) S.A.C.I., Athens, GreeceDepartment of Neurology, Medical Center of PalaioFaliro, Athens, GreeceDepartment of Neurology, MetropolitanHospital, Athens, GreeceMedical Department, Novartis (Hellas) S.A.C.I., Athens, GreeceMedical Department, Novartis (Hellas) S.A.C.I., Athens, GreeceObjectives: The primary objective of this multicentre, prospective, observational study was to assess whether there is improvement in the patients’ quality of life under treatment with rivastigmine transdermal patch, as it is evaluated both by patients and their caregivers. Compliance to treatment and safety were secondary endpoints. Methods: In total, 1509 patients with mild to moderate Alzheimer’s disease, already treated with rivastigmine transdermal patch 4.6 or 9.5 mg/24 h, were enrolled within a 2.4-month period and prospectively followed up for 2 months on an outpatient basis. The ‘Quality of Life in Alzheimer’s disease (QOL-AD): Patient and Caregiver Report’ questionnaire was used to evaluate quality of life as an effectiveness measure. Results and conclusion: A significant improvement in quality of life, as indicated by a change of 2.7 and 2.5 points in the mean patients’ and caregiver’s QOL-AD: Patient and Caregiver Report score respectively (both p < 0.001) from baseline to end of study was recorded. No serious adverse events were reported. Compliance was high, with 100% compliance reported for almost 9 out of 10 patients at study end.https://doi.org/10.1177/2050312115587795
collection DOAJ
language English
format Article
sources DOAJ
author Vassileios Vagenas
Georgios S Vlachos
Nikoleta Vlachou
Dimitrios Liakopoulos
Michail E Kalaitzakis
Michail Vikelis
spellingShingle Vassileios Vagenas
Georgios S Vlachos
Nikoleta Vlachou
Dimitrios Liakopoulos
Michail E Kalaitzakis
Michail Vikelis
A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch
SAGE Open Medicine
author_facet Vassileios Vagenas
Georgios S Vlachos
Nikoleta Vlachou
Dimitrios Liakopoulos
Michail E Kalaitzakis
Michail Vikelis
author_sort Vassileios Vagenas
title A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch
title_short A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch
title_full A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch
title_fullStr A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch
title_full_unstemmed A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch
title_sort prospective non-interventional study for evaluation of quality of life in patients with alzheimer’s disease treated with rivastigmine transdermal patch
publisher SAGE Publishing
series SAGE Open Medicine
issn 2050-3121
publishDate 2015-06-01
description Objectives: The primary objective of this multicentre, prospective, observational study was to assess whether there is improvement in the patients’ quality of life under treatment with rivastigmine transdermal patch, as it is evaluated both by patients and their caregivers. Compliance to treatment and safety were secondary endpoints. Methods: In total, 1509 patients with mild to moderate Alzheimer’s disease, already treated with rivastigmine transdermal patch 4.6 or 9.5 mg/24 h, were enrolled within a 2.4-month period and prospectively followed up for 2 months on an outpatient basis. The ‘Quality of Life in Alzheimer’s disease (QOL-AD): Patient and Caregiver Report’ questionnaire was used to evaluate quality of life as an effectiveness measure. Results and conclusion: A significant improvement in quality of life, as indicated by a change of 2.7 and 2.5 points in the mean patients’ and caregiver’s QOL-AD: Patient and Caregiver Report score respectively (both p < 0.001) from baseline to end of study was recorded. No serious adverse events were reported. Compliance was high, with 100% compliance reported for almost 9 out of 10 patients at study end.
url https://doi.org/10.1177/2050312115587795
work_keys_str_mv AT vassileiosvagenas aprospectivenoninterventionalstudyforevaluationofqualityoflifeinpatientswithalzheimersdiseasetreatedwithrivastigminetransdermalpatch
AT georgiossvlachos aprospectivenoninterventionalstudyforevaluationofqualityoflifeinpatientswithalzheimersdiseasetreatedwithrivastigminetransdermalpatch
AT nikoletavlachou aprospectivenoninterventionalstudyforevaluationofqualityoflifeinpatientswithalzheimersdiseasetreatedwithrivastigminetransdermalpatch
AT dimitriosliakopoulos aprospectivenoninterventionalstudyforevaluationofqualityoflifeinpatientswithalzheimersdiseasetreatedwithrivastigminetransdermalpatch
AT michailekalaitzakis aprospectivenoninterventionalstudyforevaluationofqualityoflifeinpatientswithalzheimersdiseasetreatedwithrivastigminetransdermalpatch
AT michailvikelis aprospectivenoninterventionalstudyforevaluationofqualityoflifeinpatientswithalzheimersdiseasetreatedwithrivastigminetransdermalpatch
AT vassileiosvagenas prospectivenoninterventionalstudyforevaluationofqualityoflifeinpatientswithalzheimersdiseasetreatedwithrivastigminetransdermalpatch
AT georgiossvlachos prospectivenoninterventionalstudyforevaluationofqualityoflifeinpatientswithalzheimersdiseasetreatedwithrivastigminetransdermalpatch
AT nikoletavlachou prospectivenoninterventionalstudyforevaluationofqualityoflifeinpatientswithalzheimersdiseasetreatedwithrivastigminetransdermalpatch
AT dimitriosliakopoulos prospectivenoninterventionalstudyforevaluationofqualityoflifeinpatientswithalzheimersdiseasetreatedwithrivastigminetransdermalpatch
AT michailekalaitzakis prospectivenoninterventionalstudyforevaluationofqualityoflifeinpatientswithalzheimersdiseasetreatedwithrivastigminetransdermalpatch
AT michailvikelis prospectivenoninterventionalstudyforevaluationofqualityoflifeinpatientswithalzheimersdiseasetreatedwithrivastigminetransdermalpatch
_version_ 1724695666585763840